CD8A and neoplasm: In contrast, and regardless of tumor type, HLA C1-ligands drove a dose-dependent expansion of KIR2DL2/S2+ CD8+ T cells in patients whose tumor growth could not be controlled and who therefore died during the follow-up period, which supports a suppressive/regulatory function for KIR2DL2/S2+ CD8+ T lymphocytes.